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Global analysis
Reduced susceptibilityFour World Health Organization (WHO) Collaborating Centres for Reference and Research on Inﬂuenza
and one WHO Collaborating Centre for the Surveillance, Epidemiology and Control of Inﬂuenza (WHO
CCs) tested 10,641 viruses collected by WHO-recognized National Inﬂuenza Centres between May
2013 and May 2014 to determine 50% inhibitory concentration (IC50) data for neuraminidase inhibitors
(NAIs) oseltamivir, zanamivir, peramivir and laninamivir. In addition, neuraminidase (NA) sequence data,
available from the WHO CCs and from sequence databases (n = 3206), were screened for amino acid sub-
stitutions associated with reduced NAI susceptibility. Ninety-ﬁve per cent of the viruses tested by the
WHO CCs were from three WHO regions: Western Paciﬁc, the Americas and Europe. Approximately 2%
(n = 172) showed highly reduced inhibition (HRI) against at least one of the four NAIs, commonly oselta-
mivir, while 0.3% (n = 32) showed reduced inhibition (RI). Those showing HRI were A(H1N1)pdm09 with
NA H275Y (n = 169), A(H3N2) with NA E119V (n = 1), B/Victoria-lineage with NA E117G (n = 1) and B/
Yamagata-lineage with NA H273Y (n = 1); amino acid position numbering is A subtype and B type specif-
ic. Although approximately 98% of circulating viruses tested during the 2013–2014 period were sensitive
to all four NAIs, a large community cluster of A(H1N1)pdm09 viruses with the NA H275Y substitution.: +81 42
bareva),
regory),
ocruz.br
Daniels),
ptibility.
ptibility.
28 E. Takashita et al. / Antiviral Research 117 (2015) 27–38from patients with no previous exposure to antivirals was detected in Hokkaido, Japan. Signiﬁcant num-
bers of A(H1N1)pdm09 NA H275Y viruses were also detected in China and the United States: phylogenet-
ic analyses showed that the Chinese viruses were similar to those from Japan, while the United States
viruses clustered separately from those of the Hokkaido outbreak, indicative of multiple resistance-emer-
gence events. Consequently, global surveillance of inﬂuenza antiviral susceptibility should be continued
from a public health perspective.
 2015 The Authors. Published by Elsevier B.V. This is anopenaccess article under the CCBY license (http://
creativecommons.org/licenses/by/4.0/).1. Introduction
Neuraminidase inhibitors (NAIs) are currently the only licenced
antiviral drugs which are effective for the treatment or prophylaxis
of seasonal inﬂuenza. National and regional antiviral stockpile poli-
cies, where they exist, rely primarily on oseltamivir and to a far les-
ser extent zanamivir, both of which have been approved for use in
many countries since 1999–2000. In Japan, two other NAIs, perami-
vir and laninamivir, have been approved for seasonal use, and
favipiravir (T705; Toyama Chemicals), a viral RNA dependent RNA
polymerase inhibitor, has recently been approved for pandemic
preparedness stockpiling only (http://www.toyama-chemical.co.
jp/eng/news/news140324e.html). Peramivir is also approved for
use in the Republic of Korea, China, and the United States.
Experience from2007–2008,when the former seasonal A(H1N1)
virus acquired oseltamivir resistance due to an H275Y neu-
raminidase (NA) amino acid substitution and spread globallywithin
12 months, has demonstrated that surveillance for NAI-resistant
viruses is essential both to guide seasonal clinical management
and inform pandemic preparedness strategies (Lackenby et al.,
2008; Collins et al., 2009; Dharan et al., 2009; García et al., 2009;
Hauge et al., 2009; Hurt et al., 2009; Meijer et al., 2009; Ujike
et al., 2010).
The former seasonal A(H1N1) H275Y virus exhibited highly
reduced inhibition (HRI) by oseltamivir and peramivir in vitro and
was shown to be clinically resistant to oseltamivir (Kawai et al.,
2009; Dharan et al., 2010; Matsuzaki et al., 2010; Saito et al.,
2010). Additional NA substitutions (R222Q, V234M, D344N and
D354G) compensated for the detrimental effect of theH275Y substi-
tution on virus ﬁtness, allowing the virus to spread efﬁciently
(Bloom et al., 2010; Rameix-Welti et al., 2011; Abed et al., 2011;
Bouvier et al., 2012).
The World Health Organization (WHO) Global Inﬂuenza
Surveillance and Response System (GISRS) expert working group
on surveillance of inﬂuenza antiviral susceptibility (WHO-AVWG)
was established in 2011 to provide advice on GISRS surveillance
strategies for inﬂuenza antiviral susceptibility and to provide prac-
tical guidance to WHO-recognized National Inﬂuenza Centres
(NICs) (WHO, 2012, 2013).
To standardise interpretation and reporting of NAI suscepti-
bility of inﬂuenza viruses to individual NAIs, clear deﬁnitions were
formulated by the WHO-AVWG using 50% inhibitory concentration
(IC50; the concentration of drug required to inhibit a standardised
amount of NA activity by 50%) fold-change thresholds, compared
to the median for viruses from the same type/subtype/lineage
showing ‘normal inhibition’ (NI) (WHO, 2012). Those showing ‘re-
duced inhibition’ (RI) are inﬂuenza A viruses that have a 10- to
100-fold increase in IC50, or inﬂuenza B viruses with a 5- to 50-fold
increase in IC50. Viruses showing HRI are inﬂuenza A viruses
with > 100-fold increase in IC50 or inﬂuenza B viruses with >50-
fold increase in IC50 (WHO, 2012).
Recently, we published a global update on the antiviral suscep-
tibility of human inﬂuenza viruses collected by NICs between May
2012 and May 2013 as the ﬁrst of a series of annual reports (Meijer
et al., 2014). Only 0.2% (n = 27) of 11,387 viruses tested showedHRI against at least one of the four NAIs, usually oseltamivir, and
mainly in A(H1N1)pdm09 viruses (21/27). Despite >99% of circu-
lating viruses being sensitive to all four NAIs during the 2012–
2013 period, localised community circulation of inﬂuenza viruses
with RI or HRI has occurred in recent years, most notably with
A(H1N1)pdm09 viruses containing the H275Y NA substitution
(Hurt et al., 2012; Garg et al., 2013). Animal models have shown
that A(H1N1)pdm09 H275Y viruses with additional NA amino acid
substitutions, V241I and N369K, have increased replication and
transmission ﬁtness (Butler et al., 2014; Abed et al., 2014).
Importantly, >97% of the N1 sequences from circulating
A(H1N1)pdm09 viruses in 2012–2013 contained the two NA sub-
stitutions V241I and N369 K that improve viral ﬁtness of the vari-
ant virus (Meijer et al., 2014). These observations, together with
those from the former seasonal A(H1N1) 2007–2008 event, illus-
trate the potential for the global emergence of ﬁt A(H1N1)pdm09
viruses with HRI by oseltamivir and peramivir.
Here, we analysed the NAI susceptibility data for inﬂuenza virus-
es collectedacross113countriesbyGISRS laboratoriesbetweenMay
2013 and May 2014 (subsequently referred to as 2013–2014).
2. Overall analysis of phenotypic antiviral susceptibility data
from WHO CCs
NIC within each country receives or collects clinical specimens
from the national laboratory network in order to conduct pre-
liminary analyses. NICs also send representative virus isolates to
at least one of the ﬁve WHO CCs (Atlanta, United States; Beijing,
China; London, United Kingdom; Melbourne, Australia, and Tokyo,
Japan; http://www.who.int/inﬂuenza/gisrs_laboratory/collaborat-
ing_centres/list/en/) for more advanced analyses. At the WHO CCs,
viruses are in general passaged one or two times in MDCK cells
before being subjected to phenotypic antiviral susceptibility testing.
FiveWHOCCs provided IC50 andNA amino acid substitution data
for virus isolates, notably for those showing RI or HRI byNAIs, recov-
ered from clinical specimens collected between week 21/2013 (20/
5/2013) through week 20/2014 (18/5/2014). When available,
patient-speciﬁc epidemiologic data such as gender, age, geographic
location, healthcare setting (community, hospitalised and sentinel/
non-sentinel specimen collection), antiviral treatment history and
immune status, were included in the analyses. All ﬁve WHO CCs
tested for oseltamivir and zanamivir susceptibility, and additionally
the Atlanta, Melbourne and Tokyo WHO CCs tested for peramivir
and laninamivir susceptibility (Supplementary Table 1).
The WHO CCs tested 10,641 viruses from the 2013–2014 period
for NAI susceptibility using local adaptations of the ﬂuorescence-
based NA enzyme inhibition assay described by Potier et al.
(1979) (Supplementary Table 1). The majority of viruses tested
were derived from community surveillance specimens, typically
collected for inﬂuenza diagnosis, and therefore prior to any NAI
treatment. However, while antiviral treatment information was
not available for many of the specimens, a proportion of viruses
were probably derived from patients during or after treatment
with NAI, in hospital or community settings. The number of viruses
tested was well distributed across the time period but with a small
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A
Fig. 1. Inﬂuenza viruses collected and tested for neuraminidase inhibitors (NAI) susceptibility during 2013–2014. (A) Week of specimen collection and virus
type/subtype/lineage; for specimens tested, a small peak in specimen collection during the Southern Hemisphere winter and a prominent peak during the Northern
Hemisphere winter were observed. (B) Number of viruses tested for susceptibility to the four NAIs by WHO region. B/Yamagata-lineage haemagglutinin – B/Victoria-lineage
neuraminidase reassortants are shown separately. The greatest numbers of viruses tested were from the Western Paciﬁc Region and the Americas. Almost all viruses were
tested for susceptibility to oseltamivir and zanamivir and a high proportion against peramivir and laninamivir.
E. Takashita et al. / Antiviral Research 117 (2015) 27–38 29peak during the Southern Hemisphere winter and a prominent
peak during the Northern Hemisphere winter (Fig. 1A).
During the 2013–2014 period, B/Yamagata-lineage haemagglu-
tinin (HA) – B/Victoria-lineage NA reassortants were detected
worldwide, notably in China. While not all B viruses had HA and
NA genes sequenced, to assess their reassortant status, 65 known
reassortants were tested and results allocated to the B/Victoria-lin-
eage dataset. Over the 12 months 5152 (48%) A(H1N1)pdm09,
2574 (24%) A(H3N2), 2311 (22%) B/Yamagata-lineage and 604
(6%) B/Victoria-lineage viruses were tested.
By WHO region (http://www.who.int/about/structure/en/), 49%
of viruses tested originated from the Western Paciﬁc Region, 38%
from the Americas, 8% from Europe, <3% from Africa, <2% from
South-East Asia and <1% from the Eastern Mediterranean Region
(Fig. 1B).
Due to differences in phenotypic NA inhibition assay method-
ology between the WHO CCs (Supplementary Table 1) all raw
IC50 data were converted into relative fold-change values to facili-
tate pooled analysis of the data from all ﬁve WHO CCs (Meijer
et al., 2014). Box-and-whisker plots based on log-transformed
IC50 fold-change data were generated using Tukey’s method to dis-
play the range of data and outliers (Fig. 2). Additionally, the box-
and-whisker plots were constructed with the Y-axis split into three
sections indicating the IC50 fold-change range for viruses classiﬁed
as NI, RI or HRI based on the criteria above (Fig. 2). Among 10,641
viruses tested, 204 viruses (2%) showed RI or HRI to one or more ofthe NAIs (Fig. 2 and Table 1). The NA genes of all 204 RI/HRI viruses
were sequenced, together with those present in clinical specimens
fromwhich 67 of the viruses were recovered. Compared to the con-
sensus NA sequences of wild-type viruses showing NI, 198 of the
RI/HRI viruses encoded an amino acid substitution in the NA glyco-
protein, of the clinical specimens available (n = 67), the same
mutations to those observed in the isolate were also present in
63 corresponding clinical specimens (Table 1).
3. A(H1N1)pdm09 viruses showing RI or HRI
Of 5152 A(H1N1)pdm09 viruses tested, 175 (3%) showed RI or
HRI by one or more of the NAIs (Fig. 2 and Table 1), of which the
NA amino acid substitution H275Y was present in 169 of those.
Twelve of the 169 H275Y variants harboured a mixed population
of H275Y variant virus and H275 wild type virus. One H275Y vari-
ant with an additional NA I223R substitution was detected in Japan
from a hospitalised patient treated with peramivir; this dual sub-
stitution has been reported previously by the United States, in a
child after prolonged treatment with oseltamivir (Nguyen et al.,
2010). The timing of specimen collection and geographic distribu-
tion of the 169 H275Y variant viruses are shown in Fig. 3. The
H275Y variants were detected between weeks 24/2013 and 15/
2014 (Fig. 3A), with 112 (66%) detected in the Western Paciﬁc
region, 56 (33%) in the Americas and one (1%) in Europe, from 10
countries in total (Fig. 3B). The NA H275Y substitution conferred
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30 E. Takashita et al. / Antiviral Research 117 (2015) 27–38151- to 2212-fold higher oseltamivir IC50 values and 87- to 2045-
fold higher peramivir IC50 values compared to wild type viruses,
but had little or no effect on zanamivir or laninamivir susceptibility
(Table 1). The H275Y/H mixed variants showed 5.4- to 584-foldhigher oseltamivir IC50 values and 4.8- to 599-fold higher perami-
vir IC50 values, depending on the proportion of the H275Y variant
in the mixed population. The H275Y/I223R variant showed HRI
with very high increases in oseltamivir (10,739-fold) and peramivir
Table 1
Virus and patient characteristics of 204 viruses showing RI or HRI, tested by WHO CCs.a
Virus n IC50 fold-change compared to reference median IC50
valuesb
NA-substitutionc Patient setting Antiviral treatment Immuno-
compromised
Oseltamivir Zanamivir Peramivir Laninamivir Virus isolate Clinical
specimen
A(H1N1)pdm09; N = 5152 156 151–2212 0.1–2.7 87–2045
(148)
0.3–4.4
(147)
H275Y H275Y
(57)
Not
available
(99)
Community (85 of
which 44 Sapporo
cluster)
Hospital (17)
Yes, oseltamivir (10),
oseltamivir + laninamivir (1), peramivir
(11), peramivir + laninamivir (1)
No (108)
Yes (2)
No (87)
12 5.4–584 0.7–2.0 4.8–599
(11)
1.0–2.7 (11) H275Y/H
mix
Not
available
Community (8)
Hospital (3)
Yes, oseltamivir (6), peramivir (4) No (10)
1 10739 18.1 7709 22.0 H275Y;
I223R
H275Y;
I223R
Hospital Yes, peramivir Unknown
1 16 7.1 nd nd D199E Not
available
Hospital Unknown No
1 23 4.9 4.2 3.6 I223K I223K Unknown Unknown Unknown
2 8.9–15 3.1–3.2 1.8–1.7 1.7–2.0 I223T I223T Unknown Unknown Unknown
1 13 7.8 5.3 2.3 I223R Not
available
Unknown Unknown Unknown
1 15 1.2 1.3 1.2 S247G S247G Unknown Unknown Unknown
A(H3N2); N = 2574 1 305 1.4 1.4 1.1 E119V E119V Unknown No Unknown
3 0.6 – 0.7 16–37 2.5–5.1 0.9–5.2 Q136K (1
mixed)
No (2)
Not
available
(1)
Unknown Unknown Unknown
1 0.9 42 7.6 6.3 Q136K/Q
mix; D151G/
D mix
Not
available
Unknown Unknown Unknown
1 1.2 10 nd nd T148K Not
available
Hospital Unknown Unknown
1 10 11 nd nd N329K Not
available
Unknown Unknown Unknown
1 10 7.8 nd nd S331R Not
available
Hospital No Unknown
1 10 8.3 nd nd S331R;
V215I
Not
available
Hospital No Unknown
B/Victoria-lineage; N = 604d 1 1.6 2.3 6.3 2.5 I114R/I mix Not
available
Unknown Unknown Unknown
1 12 1010 2326 649 E117G Not
available
Unknown Unknown Unknown
1 3.3 0.9 13 0.5 H134Y/H
mix
No Community No Unknown
1 1.2 1.4 7.5 0.8 D149N/D
mix
Not
available
Unknown Unknown Unknown
1 1.0 7.0 nd nd N151S
d Not
available
Hospital No Unknown
1 4.7 5.0 nd nd D197N
d Not
available
Hospital Unknown No
1 1.6 1.6 7.3 1.2 S440L/S mix Not
sequenced
Unknown Unknown Unknown
1 3.4 3.0 5.0 4.6 M449V Not
available
Unknown Unknown Unknown
3 0.6–4.1 0.7–8.7 0.9–6.5 0.7–4.7 None Not
available
Community (2)
Unknown(1)
Unknown No (2)
Unknown (1)
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32 E. Takashita et al. / Antiviral Research 117 (2015) 27–38(7709-fold) IC50 values and RI by zanamivir and laninamivir, with
18.1- and 22-fold IC50 increases respectively, compared to values
for A(H1N1)pdm09 viruses displaying NI by the four NAIs. The
NA H275Y substitution was conﬁrmed in 58 clinical specimens
for which sequence results were available and the NA I223R substi-
tution was conﬁrmed in the clinical specimen from which the
H275Y/I223R variant virus was isolated (Table 1).
Of the H275Y variant viruses detected in 2013–2014 where
patient setting information was available, 82% were from non-hos-
pitalised patients (Table 1). In addition, only two of the 99 patients
for whom immune status information was available, were reported
as being immunocompromised. Based on available antiviral treat-
ment information, 10 of the 12 H275Y/H mixed variants were
recovered from patients during or after treatment with oseltamivir
or peramivir. Of the remaining H275Y variants recovered, 82%
were from patients had not been treated with NAIs before speci-
men collection, suggesting that there is potential for spontaneous
emergence and spread of these resistant viruses in the community.
Indeed, a cluster of A(H1N1)pdm09 viruses with the NA H275Y
substitution was detected in 39 (29%) of 135 untreated community
cases in Sapporo, capital of Hokkaido, Japan (described in detail in
Takashita et al., 2014). In the United States, 57 oseltamivir-resis-
tant A(H1N1)pdm09 viruses were detected in 20 states with a
majority being collected from patients not exposed to oseltamivir
(Okomo-Adhiambo et al., 2015). In China, nine H275Y variant
viruses were detected in nine provinces, while the oseltamivir
exposure history of four patients was unknown, the remaining ﬁve
had no exposure to oseltamivir.
Other NA amino acid substitutions (D199E, I223K, I223T, I223R
and S247G) were detected in viruses with elevated IC50 values
(Fig. 2 and Table 1). The clinical specimens yielding four of these
isolates were available and all contained the corresponding substi-
tutions; no matching clinical specimen was available for the virus-
es carrying NA D199E or NA I223R substitutions. The IC50 fold-
changes for virus with the dual substitution NA H275Y/I223R com-
pared to those of viruses with NA H275Y or NA I223R only (Fig. 2),
shows clearly the synergistic effect of this dual substitution and
induction of RI or HRI for all four NAIs tested (Tan et al., 2013).4. A(H3N2) viruses showing RI or HRI
Nine (0.3%) A(H3N2) viruses out of 2574 tested showed RI or
HRI by oseltamivir or zanamivir (Fig. 2 and Table 1). Three of these
had a NA Q136K amino acid substitution (Table 1). Available clin-
ical specimens yielding two of these isolates did not contain the
mutation conferring the amino acid substitution prior to cell cul-
ture. However, NA Q136K substitution has been reported previous-
ly in clinical specimens (Dapat et al., 2010). One A(H3N2) virus
from the United States contained a NA E119V substitution which
conferred HRI by oseltamivir but had no effect on susceptibility
to the other NAIs. The E119V variant virus came from an oseltami-
vir-treated patient. The NA E119V substitution was detected in the
corresponding clinical specimen. NA amino acid substitutions
T148K, N329K, S331R and V215I were detected in viruses with
IC50 fold-change values that were close to the intersect between
NI and RI categories for oseltamivir and/or zanamivir. NA T148K
and D151G substitutions can emerge during culturing of
A(H3N2) viruses (Tamura et al., 2013).5. B/Victoria-lineage viruses showing RI or HRI
Of 604 B/Victoria-lineage viruses tested, 12 (2%) showed RI or
HRI by one or more of the NAIs (Fig. 2 and Table 1). One B/
Victoria-lineage virus from Bangladesh with a NA E117G substitu-
tion showed HRI by three of the four NAIs tested with a 2326-fold
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E. Takashita et al. / Antiviral Research 117 (2015) 27–38 33increase in peramivir IC50, a 1010-fold increase in zanamivir IC50, a
649-fold increase in laninamivir IC50 and RI with a 12-fold increase
in oseltamivir IC50 compared to values for B/Victoria-lineage virus-
es displaying NI by the four NAIs (Table 1). NA amino acid substi-
tutions N151S and D197N were detected in B/Yamagata-lineage
HA – B/Victoria-lineage NA reassortants. All other substitutions
identiﬁed in the isolates that were classiﬁed as having RI to zana-
mivir or peramivir require further analysis to assess whether the
amino acid substitutions observed are responsible for the changes
in IC50. Three B/Victoria-lineage viruses had IC50 values that were
close to the intersect between NI and RI categories for zanamivir
or peramivir, but no NA amino acid substitutions were detected
on sequencing.6. B/Yamagata-lineage viruses showing RI or HRI
Eight (0.3%) B/Yamagata-lineage viruses out of 2311 tested
showed RI or HRI by one or more of the NAIs (Fig. 2 and Table 1).
One B/Yamagata-lineage virus from Macau, China contained an
NA H273Y substitution which conferred HRI (103-fold increase)
by peramivir and RI (7.1-fold increase) by oseltamivir but had no
effect on susceptibility to zanamivir and laninamivir (Table 1).
The two viruses carrying NA D197N substitution yielded different
patterns of NI and RI by all NAIs, around the intersect between NI
and RI categories; only for peramivir did both show RI. The NA
D197N substitution has been observed before in B/Yamagata-lin-
eage virus and shown to confer RI by zanamivir and peramivir
(Oakley et al., 2010). One of the two D197N variant viruses, camefrom a patient during treatmentwith zanamivir, but no information
was available for the second patient. NA amino acid substitutions
N151T and S249N were detected in viruses with elevated IC50 val-
ues (Table 1). The clinical specimen yielding the S249N variant also
contained the substitution. The clinical specimen yielding the
N151T variant did not contain the substitution. Further investiga-
tion is needed to assess the role of these substitutions in altering
NAI susceptibility. Three B/Yamagata-lineage viruses had IC50 val-
ues that were around the intersect between NI and RI categories,
but NA-gene sequencing revealed no NA amino acid substitutions.7. Frequency of RI and HRI conferring NA amino acid
substitutions in sequence databases
We screened NA sequences from viruses collected during the
2013–2014 period that had been deposited in the Global
Initiative on Sharing All Inﬂuenza Data (GISAID) database, at
www.gisaid.org, and the National Center for Biotechnology
Information Inﬂuenza Virus Resource (NCBI-IVR), at www.ncbi.
nlm.nih.gov/genomes/FLU/FLU.html, for amino acid substitutions
which are known to confer clinical resistance (e.g. H275Y in
A(H1N1)pdm09 viruses), or are known to occur clinically. A list
of the amino acid substitutions that are relevant for clinical and
surveillance interpretation, reviewed and updated in May 2014
by theWHO-AVWG, is available at: http://www.who.int/inﬂuenza/
gisrs_laboratory/antiviral_susceptibility/nai_overview/en/ (accessed
21 November 2014). A total of 3206 sequences from GISAID and
NCBI-IVR databases were analysed for the presence of key NA
Table 2
Frequency of amino acid substitutions in NAs, submitted to GISAID and NCBI sequence databases, known to occur clinically and cause clinical resistance.a
Type/subtype NA amino acid
substitutionb
No. of sequences containing
the substitution (%)c
Home country patient (n) Included in phenotypic analysisd
A(N1)
H275Y + I223R 1 (0.1%) Japan (1) Yes (HRI to oseltamivir and peramivir; RI to zanamivir and peramivir)
H275Y 148 (11%) Australia (1) Yes (HRI to oseltamivir and peramivir)
China (1) Yes (HRI to oseltamivir and peramivir)
China (1) Yes (HRI to oseltamivir)
China (4) No
Dominican Republic (1) Yes (HRI to oseltamivir and peramivir)
Haiti (1) Yes (HRI to oseltamivir and peramivir)
Japan (86) Yes (HRI to oseltamivir and peramivir)
Japan (1) No
Mexico (1) Yes (HRI to oseltamivir and peramivir)
New Caledonia (1) Yes (HRI to oseltamivir and peramivir)
Spain (1) Yes (HRI to oseltamivir)
United States (48) Yes (HRI to oseltamivir and peramivir)
United States (1) No
H275Y/H 16 (1%) Brazil (1) Yes (HRI to oseltamivir and peramivir)
China (1) Yes (HRI to oseltamivir)
Japan (2) Yes (HRI to oseltamivir and peramivir)
Japan (2) Yes (HRI to oseltamivir and RI to peramivir)
Japan (2) Yes (RI to oseltamivir and HRI to peramivir)
Japan (2) Yes (RI to oseltamivir and peramivir)
Japan (1) Yes (RI to oseltamivir)
Japan (1) Yes (RI to peramivir)
Japan (1) No
Paraguay (1) Yes (RI to oseltamivir)
United States (2) Yes (NI)
a As listed in the table on the WHO website, available at: http://www.who.int/inﬂuenza/gisrs_laboratory/antiviral_susceptibility/nai_overview/en/; accessed 15 January
2015.
b Amino acid position numbering is N1 speciﬁc.
c Percentage based on the number of sequences in the ﬁnal data set after curation – see Supplementary Table 2.
d Yes indicates that the virus was analysed by a WHO CC. HRI = highly reduced inhibition, RI = reduced inhibition, NI = normal inhibition, assessed by in vitro assay for the
neuraminidase inhibitors indicate.
34 E. Takashita et al. / Antiviral Research 117 (2015) 27–38amino acid substitutions, following curation for quality, sequence
length and duplication (Supplementary Table 2). The majority of
sequences in the databases were from viruses collected through
the GISRS network and characterised via phenotypic analysis in
GISRS laboratories. Of 1328 N1 sequences from A(H1N1)pdm09
viruses, 165 (12%) contained NA H275Y substitution, of which 16
showed NA 275Y/H polymorphism and one carried NA H275Y/
I223R dual substitutions (Table 2). The H275Y/I223R variant virus
had been analysed by NA inhibition assay at a WHO CC and is
included in Fig. 2 and Table 1. The 165 H275Y variant viruses were
derived from 11 countries. Seven H275Y variant viruses were in
the sequence database but not present in the WHO CCs IC50
dataset. Phylogenetic analysis of NA (Fig. 4A) and HA (Fig. 4B) gene
sequences showed, in both phylogenetic trees, that the H275Y
variant viruses did not emerge from a common source. However,
the H275Y variants from China were genetically similar to those
from the Hokkaido cluster.
Analysis of the available sequences also identiﬁed 25 N1
sequences from A(H1N1)pdm09 viruses containing D199N substi-
tution, of which seven originated from Bulgaria, and four inﬂuenza
B NA sequences containing D197N substitution (Table 3). Twenty-
one of the 25 N1 D199N variants and three of the four B NA D197N
variants had been analysed by NA inhibition assay at the WHO CCs.
The A(H1N1)pdm09 viruses with NA D199N substitution showed
NI. The inﬂuenza B viruses containing NA D197N substitution
showed RI to one or more of the NAIs. These results are consistent
with the AVWG table (http://www.who.int/inﬂuenza/gisrs_labora-
tory/antiviral_susceptibility/nai_overview/en/). Two N2 sequences
contained E119V substitution, with no evidence for 119E/V mix-
tures, and both E119V variants were analysed by NA inhibition
assay at the WHO CCs. One showed HRI to oseltamivir and is
included in Fig. 2 and Table 1 and the other showed NI. In theAVWG table, it is listed that the NA E119V substitution confers
18-fold (RI) to 2057-fold (HRI) increases in oseltamivir IC50.8. Concluding remarks
The WHO-AVWG was able to perform this global analysis on
inﬂuenza antiviral susceptibility thanks to NICs within the WHO
GISRS fulﬁlling their Terms of Reference by collecting inﬂuenza
virus positive clinical specimens and sharing a representative pro-
portion of them, or viruses recovered, with the WHO CCs for fur-
ther detailed characterisation (Kitler et al., 2002).
Based on our current analysis, approximately 98% of all viruses
circulating during 2013–2014 were sensitive to all four NAIs and
therefore these drugs remain an appropriate choice for the treat-
ment and prophylaxis of inﬂuenza virus infections. However, a
large community cluster of A(H1N1)pdm09 viruses with the NA
H275Y substitution occurred in Hokkaido, Japan between
November 2013 and February 2014. In 2011, a widespread com-
munity cluster of NA H275Y variant A(H1N1)pdm09 viruses
occurred in Newcastle, Australia (Hurt et al., 2012). The latter
H275Y variant viruses possessed V241I and N369K substitutions
in the NA which partially overcame the detrimental effects of the
H275Y substitution on virus ﬁtness (Butler et al., 2014; Abed
et al., 2014). Almost all recently circulating A(H1N1)pdm09 viruses
possess the NA V241I and N369K substitutions, indicating
increased risk of H275Y variant viruses emerging and spreading
globally. The Hokkaido cluster viruses carried these two substitu-
tions and shared NA N386K substitution with the H275Y variant
viruses detected in China. Therefore, the H275Y variant viruses of
the Hokkaido cluster and those of China may be derived from a
common ancestor.
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Fig. 4. Evolutionary relationships among inﬂuenza A(H1N1)pdm09 virus neuraminidase (NA) and haemagglutinin (HA) genes. The phylogenetic trees were constructed using
RAxML (http://sco.h-its.org/exelixis/software.html), drawn using FigTree (http://tree.bio.ed.ac.uk/software/ﬁgtree/) and annotated using Adobe Illustrator (http://www.
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18 May 2014 were analysed: the virus selection included 50 with NA H275 and 62 with NA H275Y amino acid substitution and seven with NA H275Y/H (mix). A/California/
07/2009 virus was used as a reference for ancestry (root) and numbering. Both trees are annotated in the same way: (i) viruses carrying NA H275Y substitution are marked by
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A/California/07/2009 Apr USA
A/Hyogo/1190/2014 Jan JPN
A/Hawaii/03/2014 Feb USA
A/Hiroshima/57/2014 Apr JPN     I223R
A/Texas/09/2014 Jan USA
A/Chongqing-Yuzhong/Swl11434/2013 Oct CHN     mix
A/Colorado/03/2014 Jan USA
A/Osaka/6/2014 Jan JPN
A/California/NHRC423502/2014 USA
A/Saitama/48/2014 Feb JPN
A/Brazil/9061/2014 Mar BRA     mix
A/Beijing-Xicheng-Nan-Pian/SWL11619/2013 Sep CHN
A/Mississippi/30/2013 Nov USA
A/New Caledonia/16/2013 Jul NCL
A/North Dakota/03/2013 Oct USA S247G
A/Mexico/818/2014 Feb MEX
A/Switzerland/10015059/2014 Feb CHE
A/Hokkaido/4/2014 Jan JPN
A/Maryland/04/2014 Feb USA
A/Gifu-C/21/2014 Jan JPN
A/Cyprus/F79/2014 Feb CYP S247N
A/Sapporo/119/2013 Dec JPN
A/Utah/10/2013 Oct USA    mix
A/Pennsylvania/14/2014 Jan USA
A/El Salvador/2260/2013 Nov SLV I223T
A/New Caledonia/26/2014 Mar NCL
A/Guizhou-Nanming/Swl11969/2013 Nov CHN
A/New York/WC-LVD-14-058/2014 USA
A/Florida/19/2013 Jul USA
A/Nevada/24/2013 Dec USA
A/Pennsylvania/05/2014 Feb USA
A/Pennsylvania/15/2014 Jan USA
A/New Caledonia/22/2013 Jul NCL
A/Fukui/29/2014 Feb JPN
A/Kanagawa/13/2014 Jan JPN
A/Panama/313202/2013 Jun PAN
A/Hungary/366/2014 Jan HUN
A/Mississippi/28/2013 Dec USA
A/Louisiana/01/2014 Jan USA
A/Malaysia/7/2014 Feb MYS
A/Louisiana/07/2013 Oct USA
A/Shaanxi-Hancheng/Swl310/2013 Dec CHN
A/Belgium/14S0252/2014 Mar BEL
A/Panama/313106/2013 Jun PAN
A/Sapporo/69/2014 Feb JPN     mix
A/Aichi/75/2014 Feb JPN I223T
A/Tokyo/32146/2014 Feb JPN
A/Malaysia/2/2014 Jan MYS I223R
A/California/06/2014 Feb USA
A/Mississippi/29/2013 Nov USA
A/California/NHRC421018/2014 USA
A/Madrid/120/2014 Jan ESP
A/Peru/152/2013 Jun PER
A/Yamaguchi/43/2013 Dec JPN
A/Gifu-C/18/2014 Feb JPN D199N
A/Poland/2398/2014 Apr POL
A/New York/33/2013 Dec USA
A/New Mexico/04/2014 Feb USA
A/Goroka/27/2013 Jul PNG
A/Hiroshima-C/26/2014 Feb JPN
A/Sapporo/65/2014 Feb JPN
A/Victoria/229/2013 Nov AUS
A/Lisboa/Rl99/2014 Jan PRT     mix
A/Sapporo/8/2014 Jan JPN
A/South Australia/19/2013 May AUS
A/Suphanburi/234/2014 Apr THA
A/Lisboa/127/2014 Feb PRT
A/Colorado/27/2013 Dec USA
A/Sapporo/22/2014 Jan JPN
A/New York/WC-LVD-14-001/2014 Jan USA
A/Osaka-C/44/2014 Jan JPN
A/India/1968/2013 Jul IND
A/Catalonia/6634s/2013 Dec ESP
A/New Caledonia/1/2014 Mar NCL
A/Louisiana/35/2013 Dec USA
A/Mississippi/01/2014 Jan USA I223K
A/Kochi/2/2014 Jan JPN
A/California/59/2013 Dec USA 
A/Texas/100/2013 Dec USA
A/Chongqing-Banan/Swl1690/2013 Nov CHN
A/Florida/73/2013 Dec USA
A/Hokkaido/3/2014 Jan JPN
A/Sichuan-Wuhou/Swl2259/2013 Sep CHN
A/Malaysia/4/2014 Jan MYS
A/New York/WC-LVD-13-021/2013 Dec USA
A/Virginia/02/2014 Jan USA
A/Ohio/01/2014 Feb USA I223K
A/Pennsylvania/17/2014 Feb USA
A/Mie/27/2013 Dec JPN
A/California/01/2014 Jan USA
A/Utah/02/2014 Feb USA
A/Dominican Republic/7626/2013 Jun DOM
A/Sapporo/1/2014 Jan JPN
A/Virginia/04/2014 Feb USA
A/Sapporo/81/2014 Feb JPN
A/Kazakhstan/3317/2013 Dec KAZ
A/Hubei-Wuchang/Swl1322/2013 Nov CHN
A/South Africa/4042/2014 May ZAF
A/Shanghai-Changning/Swl1621/2013 Dec CHN
A/Paraguay/91/2013 Jun PRY      mix
A/Perth/111/2013 Aug AUS
A/Toulouse/2730/2013 Nov FRA
A/India/2167/2013 Jul IND
A/Sichuan-Qingyang/Swl1544/2013 Sep CHN
A/Ehime/1/2014 Jan JPN
A/North Carolina/21/2013 Nov USA    mix
A/Mississippi/09/2013 Oct USA
A/Denmark/101/2013 Dec DNK
A/Mississippi/31/2013 Dec USA
A/Washington/05/2014 Feb USA
A/Fukui/56/2014 Mar JPN
A/Pennsylvania/02/2014 Jan USA
A/New Jersey/09/2013 Sep USA
A/Newcastle/5/2014 Jan AUS
A/Osaka-C/57/2014 Feb JPN
A/North Carolina/04/2014 Feb USA
A/Louisiana/38/2013 Dec USA
A/Tennessee/05/2014 Feb USA
A/Alabama/19/2013 Dec USA
A/Haiti/2030/2013 Jun HTI
S84N
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Fig. 4 (continued)
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Asia and East Mediterranean regions being available for analysis,
this pooled analysis of IC50 data from the ﬁve WHO CCs offers
the best opportunity to gain a robust global picture of the inci-
dence of RI/HRI by NAIs and the relatedness of the NAI resistant
viruses.
The majority of NA sequences in the GISAID sequence database
are deposited by the WHO CCs. There are an increasing number ofGISRS NICs with NA sequencing capability, but this is not reﬂected
in the current analysis as many of the submitted sequences are
incomplete and do not cover all known reduced NAI susceptibility
conferring NA amino acid substitution positions. These laborato-
ries should be encouraged to perform full-length NA-gene
sequencing and submit available sequences in a timely manner
as it would add signiﬁcant value to global NAI susceptibility
surveillance efforts.
Table 3
Frequency of amino acid substitutions in NAs, submitted to GISAID and NCBI sequence databases, known to occur clinically but currently of unknown impact, that cause reduced
sensitivity in vitro.a
Type/subtype NA amino acid
substitutionb
No. of sequences containing
the substitution (%)c
Home country
patient (n)
Included in phenotypic analysisd
A(N1) D199N 25 (1.9 %) Bulgaria (7) Yes (NI)
Dominican Republic (1) Yes (NI)
Georgia (1) Yes (NI)
Germany (1) Yes (NI)
Italy (1) No
Italy (2) Yes (NI)
Japan (2) Yes (NI)
Latvia (1) Yes (NI)
Malaysia (1) Yes (NI)
Poland (2) No
United Kingdom (1) No
United States (5) Yes (NI)
I223R 2 (0.2%) Belgium (1) No
Malaysia (1) Yes (RI to oseltamivir)
N295S 0
A(N2) E119V 2 (0.2%) United Kingdom (1) Yes (NI)
United States (1) Yes (HRI to oseltamivir)
R292K 0
N294S 0
Be R150K 0
D197E 0
D197N 4 (0.5%) China (HA Yam/NA Vic) (1) Yes (RI to zanamivir and oseltamivir)
China (HA Yam/NA Yam) (1) No
Japan (HA Yam/NA Yam) (1) Yes (RI to zanamivir, oseltamivir, peramivir and laninamivir)
Japan (HA Yam/NA Yam) (1) Yes (RI to oseltamivir and peramivir)
I221T 0
N294S 0
G407S 0
a As listed in the table on the WHO website, available at: http://www.who.int/inﬂuenza/gisrs_laboratory/antiviral_susceptibility/nai_overview/en/; accessed 15 January
2015.
b Amino acid position numbering is A subtype and B type speciﬁc.
c Percentage based on the number of sequences in the ﬁnal data set after curation – see Supplementary Table 2.
d Yes indicates that the virus was analysed by a WHO CC. NI = normal inhibition; RI = reduced inhibition; HRI = highly reduced inhibition, assessed by in vitro assay for the
neuraminidase inhibitors (NAIs) indicated.
e The H273Y substitution found in the WHO CC data was not included here, because it did not fulﬁl the requirements for screening: a new substitution should be present in
the clinical specimen and more than a single occurrence if in a patient who has not been treated with a NAI.
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panying clinical specimens or virus isolates being referred to the
WHO CCs remains a limitation in determining the signiﬁcance of
RI/HRI virus detection. NICs often cannot obtain this information
on all samples, particularly when they are received from non-sen-
tinel surveillance systems. Follow-up of individual samples requires
signiﬁcant, often one-to-one interaction with sub-national labora-
tories or physicians which is not possible for some NICs. In addition,
NAI susceptibility analysis of samples for surveillance purposesmay
not be performed in a timely manner, making the collection of clin-
ical andepidemiologic data for characterisationof the risk factors for
NAI-RI/HRI virus infection difﬁcult. Knowledge of whether the sam-
ple originated frompatients in the community or hospitals canmore
easily be obtained. The WHO-AVWG is currently developing the
WHO database (FluNet) to collect this basic information, together
with H275Y screening data for inﬂuenza A(H1N1)pdm09 viruses,
from all NICs who perform such testing. This basic information,
which can also be supplied with the samples referred to the WHO
CCs, does at least facilitate screening for increased incidence of
viruses with HRI from untreated patients in the community, such
as detected in Japan in 2013–2014 and Australia in 2011.
This is the second global update on inﬂuenza NAI susceptibility
based on analysing data generated byWHOCCs on samples received
from theGISRS laboratories. Overall, the proportion of viruses show-
ing RI/HRI was similar between the two years, approximately 1% in
2012–2013 and 2% in 2013–2014. The slight increase in 2013–2014
is due to several clusters of untreated cases of A(H1N1)pdm09virus-
es carrying NA H275Y substitution in China, Japan and the UnitedStates. Only 1% of A(H1N1)pdm09 viruses exhibited RI/HRI in
2012–2013, comparedwith 3% in 2013–2014. Rates of RI/HRI detec-
tion in A(H3N2) (0.4% vs 0.3%), B/Victoria- (1% vs 2%) and B/
Yamagata- (0.3% both years) lineage viruses have remained very
similar for the two seasons analysed to date. Prevalence of RI/HRI
viruses has consistently been higher for B/Victoria-lineage over B/
Yamagata-lineage viruses. This could be a reﬂection of the overall
number of viruses analysed (more B/Yamagata-lineage in both sea-
sons) but could also be an indication of a slightly higher tendency for
B/Victoria-lineage NA to tolerate RI/HRI conferring substitutions.
This could merit further investigation, taking into account reassor-
tant events between the two lineages, notably the recent emergence
of B/Yamagata-lineage HA – B/Victoria-lineage NA reassortants.
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